<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607487</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54707-203</org_study_id>
    <nct_id>NCT03607487</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa</brief_title>
  <official_title>A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment
      period in men and women with moderate to severe hidradenitis suppurativa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">August 13, 2019</completion_date>
  <primary_completion_date type="Actual">August 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance of INCB054707</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral volume of distribution of INCB054707</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving a Hidradenitis Suppurativa Clinical Response (HiSCR) at each visit</measure>
    <time_frame>From screening up to 16 weeks</time_frame>
    <description>HiSCR defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving an AN count of 0 to 2 at each visit</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>AN defined as abscess and inflammatory nodule count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the Hidradenitis Suppurativa Pain Numeric Rating Scale (HS Pain NRS) scores at each visit</measure>
    <time_frame>From baseline up to 12 weeks</time_frame>
    <description>An 11-point scale used to assess the worst skin pain and the average skin pain due to HS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the modified Sartorius scale score</measure>
    <time_frame>From baseline up to week 8</time_frame>
    <description>Scale measuring the severity of HS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the number of draining fistulas count at each visit.</measure>
    <time_frame>From baseline up to 16 weeks</time_frame>
    <description>Defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants at each category of Hurley Stage</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Investigator-determined Hurley Stage (I, II, or III) of HS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with change from baseline in Hurley Stage</measure>
    <time_frame>From baseline to Week 8</time_frame>
    <description>Proportion of participants at each category of Hurley Stage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of participants in each HS Patient Global Impression of Change (PGIC) category during the treatment period</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Participant self-administered 1-item questionnaire that assesses change in the severity of skin in the HS area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual measurements in HS-PGIC at each visit</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Participant self-administered 1-item questionnaire that assesses change in the severity of skin in the HS area.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB054707 at the Cohort 1 dose or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB054707 at the Cohort 2 dose or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB054707 at the Cohort 3 dose or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054707</intervention_name>
    <description>INCB054707 tablet administered orally once daily at the protocol-defined dose.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet administered orally once daily.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6
             months before screening.

          -  Stable course of HS for at least 90 days before screening, as determined by the
             investigator.

          -  HS lesions present in at least 2 distinct anatomic areas, 1 of which must be Hurley
             Stage II or Hurley Stage III at screening.

          -  Total AN count of at least 3 at screening and baseline.

          -  Willingness to avoid pregnancy or fathering children.

        Exclusion Criteria:

          -  Women who are currently pregnant or lactating.

          -  Presence of &gt; 20 draining fistulas at screening and baseline.

          -  Participants with protocol-defined concurrent conditions or history of other diseases.

          -  Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF),
             defined as ≥ 450 msec.

          -  Positive test result for tuberculosis from the QuantiFERON-TB Gold test, or T-SPOT.TB
             test at screening.

          -  A history of active tuberculosis (treated or untreated) or a history of untreated
             latent tuberculosis.

          -  Positive serology test results for HIV, hepatitis B surface antigen, hepatitis B virus
             core antibody, or hepatitis C virus (HCV antibody with positive HCV-RNA) at screening.

          -  Decreased blood cell counts at screening per protocol-defined criteria.

          -  Severely impaired liver function (Child-Pugh Class C) or alanine aminotransferase or
             aspartate aminotransferase levels ≥ 1.5 × upper limit of normal at screening.

          -  Impaired renal function with serum creatinine &gt; 1.5 mg/dL at screening.

          -  Use of protocol-prohibited medications.

          -  Known or suspected allergy to INCB054707 or any component of the study drug.

          -  Known history of clinically significant drug or alcohol abuse in the last year before
             baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Butler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wiseman Dermatology Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brunswick Dermatology Center</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SimcoDerm Medical and Surgical Dermatology Center</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEffects</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Dermatology Center</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research, Inc</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Isabelle Delorme Inc.</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <zip>J2B 5L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dre Angelique Gagne-Henley MD inc.</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 7E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University hospital Afdeling for hud- og kønssygdomme</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sjællands universitetshospital, Roskilde Dermatologisk afdeling</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Abteilung für Dermatologie</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr-Universität Bochum Dermatologische Studienambulanz Haus J, 1. Etage</name>
      <address>
        <city>Bochum</city>
        <state>Noth Rhine-Westphalia</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Institut für Entzündungsmedizin</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hidradenitis suppurativa</keyword>
  <keyword>Janus kinase (JAK) inhibitor</keyword>
  <keyword>skin disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

